Retinopathy in newly-diagnosed systemic lupus erythematosus: should we screen for ocular involvement?
Disease activity
Ocular manifestations
Retinopathy
Systemic lupus erythematosus
Vasculopathy
Journal
BMC rheumatology
ISSN: 2520-1026
Titre abrégé: BMC Rheumatol
Pays: England
ID NLM: 101738571
Informations de publication
Date de publication:
01 Oct 2021
01 Oct 2021
Historique:
received:
09
03
2021
accepted:
12
05
2021
entrez:
1
10
2021
pubmed:
2
10
2021
medline:
2
10
2021
Statut:
epublish
Résumé
Ocular manifestations are common in systemic lupus erythematosus (SLE). Retinopathy has previously been linked to disease severity and might have a significant impact on the patient's quality of life and has also been associated with a poor prognosis in SLE. This study aimed to determine the prevalence of retinopathy among patients who are newly diagnosed with SLE. In a cross-sectional study, patients diagnosed with SLE at a tertiary referral clinic were assessed for inclusion between March 2016 and March 2017. Patients who had received treatment for SLE at any time were excluded, as well as patients with hypertension, diabetes mellitus, and coagulopathy. Clinical findings and laboratory test results were recorded, and patients were examined by an ophthalmologist for evidence of retinal pathologies. SLE disease activity index was also calculated for all patients. With 114 patients included in the final analysis, we found a prevalence of 15.8% for retinopathy among newly-diagnosed SLE patients. Cotton-wool spots were the most common finding (78%). Patients with retinopathy had significantly lower hemoglobin levels, C3 and C4 concentrations, and higher ANA and Anti-dsDNA levels. Also, patients with retinopathy had a significantly higher SLE DAI score. We found a relatively high rate of retinopathy in SLE patients at the time of their initial diagnosis. Our findings suggest that retinopathy is an early manifestation of the disease. Ophthalmologic screening might be considered for SLE patients at the time of diagnosis, especially for those with severe disease. We also encourage researchers to further evaluate the correlation between retinopathy and disease activity, and the prognosis of ocular involvement.
Sections du résumé
BACKGROUND
BACKGROUND
Ocular manifestations are common in systemic lupus erythematosus (SLE). Retinopathy has previously been linked to disease severity and might have a significant impact on the patient's quality of life and has also been associated with a poor prognosis in SLE. This study aimed to determine the prevalence of retinopathy among patients who are newly diagnosed with SLE.
METHODS
METHODS
In a cross-sectional study, patients diagnosed with SLE at a tertiary referral clinic were assessed for inclusion between March 2016 and March 2017. Patients who had received treatment for SLE at any time were excluded, as well as patients with hypertension, diabetes mellitus, and coagulopathy. Clinical findings and laboratory test results were recorded, and patients were examined by an ophthalmologist for evidence of retinal pathologies. SLE disease activity index was also calculated for all patients.
RESULTS
RESULTS
With 114 patients included in the final analysis, we found a prevalence of 15.8% for retinopathy among newly-diagnosed SLE patients. Cotton-wool spots were the most common finding (78%). Patients with retinopathy had significantly lower hemoglobin levels, C3 and C4 concentrations, and higher ANA and Anti-dsDNA levels. Also, patients with retinopathy had a significantly higher SLE DAI score.
CONCLUSIONS
CONCLUSIONS
We found a relatively high rate of retinopathy in SLE patients at the time of their initial diagnosis. Our findings suggest that retinopathy is an early manifestation of the disease. Ophthalmologic screening might be considered for SLE patients at the time of diagnosis, especially for those with severe disease. We also encourage researchers to further evaluate the correlation between retinopathy and disease activity, and the prognosis of ocular involvement.
Identifiants
pubmed: 34593048
doi: 10.1186/s41927-021-00203-5
pii: 10.1186/s41927-021-00203-5
pmc: PMC8485475
doi:
Types de publication
Journal Article
Langues
eng
Pagination
34Informations de copyright
© 2021. The Author(s).
Références
Ocul Immunol Inflamm. 2011 Dec;19(6):422-5
pubmed: 22106910
BMJ Case Rep. 2020 Jan 26;13(1):
pubmed: 31988053
Clin Exp Med. 2018 May;18(2):135-149
pubmed: 29243035
Autoimmun Rev. 2019 Mar;18(3):247-254
pubmed: 30639641
Ocul Immunol Inflamm. 2018;26(8):1154-1165
pubmed: 30096011
Rheumatol Int. 2018 Aug;38(8):1495-1501
pubmed: 29948002
Lupus. 2020 Mar;29(3):283-289
pubmed: 31992127
Curr Opin Ophthalmol. 2002 Dec;13(6):404-10
pubmed: 12441845
Reumatologia. 2021;59(2):85-89
pubmed: 33976461
J Rheumatol. 2002 Feb;29(2):288-91
pubmed: 11838846
Lupus. 2006;15(1):3-12
pubmed: 16482739
Autoimmune Dis. 2012;2012:290898
pubmed: 22811887
Rheumatol Int. 2013 Jun;33(6):1637-42
pubmed: 22202921
Eur J Rheumatol. 2020 Sep 03;:
pubmed: 32910761
Lupus. 2017 Apr;26(5):522-528
pubmed: 28394224
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Arthritis Rheum. 1986 Sep;29(9):1152-6
pubmed: 3753541
Eur J Gastroenterol Hepatol. 2021 Apr 9;:
pubmed: 33852509